BlossomHill Therapeutics will present data on BH-30643, a macrocyclic, mutant-selective OMNI-EGFR inhibitor designed to target multiple EGFR mutations in non-small cell lung cancer, at the 2025 AACR Annual Meeting.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.